Neutrophil-to-Lymphocyte Ratio Predicts Outcome in Limited Disease Small-cell Lung Cancer

Lukas Käsmann, Louisa Bolm, Steven E. Schild, Stefan Janssen, Dirk Rades

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Introduction: Patients with limited disease small-cell lung cancer (SCLC) receive radiochemotherapy followed by prophylactic cranial irradiation. The prognosis of these patients remains poor with a median survival of 16–24 months. Systemic inflammation was suggested as an important prognostic factor for outcomes. This study investigated the impact of systemic inflammation measured with neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) at first diagnosis in patients with limited disease SCLC for outcomes. Methods: Data of 65 patients receiving radiochemotherapy for limited disease SCLC were analyzed. NLR and PLR were obtained from blood sample at first diagnosis of SCLC and 12 characteristics including gender, age, ECOG, T-category, N-category, pack years, smoking during radiotherapy, respiratory insufficiency, hemoglobin levels during radiotherapy, radiation dose (<56 vs. ≥56 Gy), concurrent radiochemotherapy, and prophylactic cranial irradiation (PCI) were evaluated for local control, metastasis-free survival, and overall survival. Results: Survival rates at 1, 2, and 3 years were 71, 45, and 28%, respectively. Median survival time was 20 months. Independent factors for improved survival were NLR < 4 (p = 0.03), ECOG 0–1 (p = 0.002), and PCI (p = 0.015). Lower T-category was an independent positive factor of local control (p = 0.035). Improved metastasis-free survival was associated with NLR < 4 (p = 0.011), ECOG 0–1 (p = 0.002), N-category 0–1 (p = 0.048), non-smoking during radiotherapy (p = 0.009), and PCI (p = 0.006). Conclusion: NLR was found to be an independent prognostic factor for overall survival. The evaluation of NLR can help identify patients with poor prognosis and appears a useful prognostic marker in clinical practice. A prospective analysis is warranted to confirm these findings.

Original languageEnglish (US)
Pages (from-to)217-224
Number of pages8
JournalLung
Volume195
Issue number2
DOIs
StatePublished - Apr 1 2017

Fingerprint

Small Cell Lung Carcinoma
Neutrophils
Lymphocytes
Cranial Irradiation
Survival
Chemoradiotherapy
Radiotherapy
Blood Platelets
Neoplasm Metastasis
Inflammation
Respiratory Insufficiency
Hemoglobins
Survival Rate
Biomarkers
Smoking
Radiation

Keywords

  • Limited disease
  • Neutrophil-to-lymphocyte ratio
  • Outcomes
  • Prognostic factors
  • Small-cell lung cancer

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Käsmann, L., Bolm, L., Schild, S. E., Janssen, S., & Rades, D. (2017). Neutrophil-to-Lymphocyte Ratio Predicts Outcome in Limited Disease Small-cell Lung Cancer. Lung, 195(2), 217-224. https://doi.org/10.1007/s00408-017-9976-6

Neutrophil-to-Lymphocyte Ratio Predicts Outcome in Limited Disease Small-cell Lung Cancer. / Käsmann, Lukas; Bolm, Louisa; Schild, Steven E.; Janssen, Stefan; Rades, Dirk.

In: Lung, Vol. 195, No. 2, 01.04.2017, p. 217-224.

Research output: Contribution to journalArticle

Käsmann, L, Bolm, L, Schild, SE, Janssen, S & Rades, D 2017, 'Neutrophil-to-Lymphocyte Ratio Predicts Outcome in Limited Disease Small-cell Lung Cancer', Lung, vol. 195, no. 2, pp. 217-224. https://doi.org/10.1007/s00408-017-9976-6
Käsmann, Lukas ; Bolm, Louisa ; Schild, Steven E. ; Janssen, Stefan ; Rades, Dirk. / Neutrophil-to-Lymphocyte Ratio Predicts Outcome in Limited Disease Small-cell Lung Cancer. In: Lung. 2017 ; Vol. 195, No. 2. pp. 217-224.
@article{d5ef5da112cf4f2f80550455225f28c4,
title = "Neutrophil-to-Lymphocyte Ratio Predicts Outcome in Limited Disease Small-cell Lung Cancer",
abstract = "Introduction: Patients with limited disease small-cell lung cancer (SCLC) receive radiochemotherapy followed by prophylactic cranial irradiation. The prognosis of these patients remains poor with a median survival of 16–24 months. Systemic inflammation was suggested as an important prognostic factor for outcomes. This study investigated the impact of systemic inflammation measured with neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) at first diagnosis in patients with limited disease SCLC for outcomes. Methods: Data of 65 patients receiving radiochemotherapy for limited disease SCLC were analyzed. NLR and PLR were obtained from blood sample at first diagnosis of SCLC and 12 characteristics including gender, age, ECOG, T-category, N-category, pack years, smoking during radiotherapy, respiratory insufficiency, hemoglobin levels during radiotherapy, radiation dose (<56 vs. ≥56 Gy), concurrent radiochemotherapy, and prophylactic cranial irradiation (PCI) were evaluated for local control, metastasis-free survival, and overall survival. Results: Survival rates at 1, 2, and 3 years were 71, 45, and 28{\%}, respectively. Median survival time was 20 months. Independent factors for improved survival were NLR < 4 (p = 0.03), ECOG 0–1 (p = 0.002), and PCI (p = 0.015). Lower T-category was an independent positive factor of local control (p = 0.035). Improved metastasis-free survival was associated with NLR < 4 (p = 0.011), ECOG 0–1 (p = 0.002), N-category 0–1 (p = 0.048), non-smoking during radiotherapy (p = 0.009), and PCI (p = 0.006). Conclusion: NLR was found to be an independent prognostic factor for overall survival. The evaluation of NLR can help identify patients with poor prognosis and appears a useful prognostic marker in clinical practice. A prospective analysis is warranted to confirm these findings.",
keywords = "Limited disease, Neutrophil-to-lymphocyte ratio, Outcomes, Prognostic factors, Small-cell lung cancer",
author = "Lukas K{\"a}smann and Louisa Bolm and Schild, {Steven E.} and Stefan Janssen and Dirk Rades",
year = "2017",
month = "4",
day = "1",
doi = "10.1007/s00408-017-9976-6",
language = "English (US)",
volume = "195",
pages = "217--224",
journal = "Lung",
issn = "0341-2040",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Neutrophil-to-Lymphocyte Ratio Predicts Outcome in Limited Disease Small-cell Lung Cancer

AU - Käsmann, Lukas

AU - Bolm, Louisa

AU - Schild, Steven E.

AU - Janssen, Stefan

AU - Rades, Dirk

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Introduction: Patients with limited disease small-cell lung cancer (SCLC) receive radiochemotherapy followed by prophylactic cranial irradiation. The prognosis of these patients remains poor with a median survival of 16–24 months. Systemic inflammation was suggested as an important prognostic factor for outcomes. This study investigated the impact of systemic inflammation measured with neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) at first diagnosis in patients with limited disease SCLC for outcomes. Methods: Data of 65 patients receiving radiochemotherapy for limited disease SCLC were analyzed. NLR and PLR were obtained from blood sample at first diagnosis of SCLC and 12 characteristics including gender, age, ECOG, T-category, N-category, pack years, smoking during radiotherapy, respiratory insufficiency, hemoglobin levels during radiotherapy, radiation dose (<56 vs. ≥56 Gy), concurrent radiochemotherapy, and prophylactic cranial irradiation (PCI) were evaluated for local control, metastasis-free survival, and overall survival. Results: Survival rates at 1, 2, and 3 years were 71, 45, and 28%, respectively. Median survival time was 20 months. Independent factors for improved survival were NLR < 4 (p = 0.03), ECOG 0–1 (p = 0.002), and PCI (p = 0.015). Lower T-category was an independent positive factor of local control (p = 0.035). Improved metastasis-free survival was associated with NLR < 4 (p = 0.011), ECOG 0–1 (p = 0.002), N-category 0–1 (p = 0.048), non-smoking during radiotherapy (p = 0.009), and PCI (p = 0.006). Conclusion: NLR was found to be an independent prognostic factor for overall survival. The evaluation of NLR can help identify patients with poor prognosis and appears a useful prognostic marker in clinical practice. A prospective analysis is warranted to confirm these findings.

AB - Introduction: Patients with limited disease small-cell lung cancer (SCLC) receive radiochemotherapy followed by prophylactic cranial irradiation. The prognosis of these patients remains poor with a median survival of 16–24 months. Systemic inflammation was suggested as an important prognostic factor for outcomes. This study investigated the impact of systemic inflammation measured with neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) at first diagnosis in patients with limited disease SCLC for outcomes. Methods: Data of 65 patients receiving radiochemotherapy for limited disease SCLC were analyzed. NLR and PLR were obtained from blood sample at first diagnosis of SCLC and 12 characteristics including gender, age, ECOG, T-category, N-category, pack years, smoking during radiotherapy, respiratory insufficiency, hemoglobin levels during radiotherapy, radiation dose (<56 vs. ≥56 Gy), concurrent radiochemotherapy, and prophylactic cranial irradiation (PCI) were evaluated for local control, metastasis-free survival, and overall survival. Results: Survival rates at 1, 2, and 3 years were 71, 45, and 28%, respectively. Median survival time was 20 months. Independent factors for improved survival were NLR < 4 (p = 0.03), ECOG 0–1 (p = 0.002), and PCI (p = 0.015). Lower T-category was an independent positive factor of local control (p = 0.035). Improved metastasis-free survival was associated with NLR < 4 (p = 0.011), ECOG 0–1 (p = 0.002), N-category 0–1 (p = 0.048), non-smoking during radiotherapy (p = 0.009), and PCI (p = 0.006). Conclusion: NLR was found to be an independent prognostic factor for overall survival. The evaluation of NLR can help identify patients with poor prognosis and appears a useful prognostic marker in clinical practice. A prospective analysis is warranted to confirm these findings.

KW - Limited disease

KW - Neutrophil-to-lymphocyte ratio

KW - Outcomes

KW - Prognostic factors

KW - Small-cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=85017284492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017284492&partnerID=8YFLogxK

U2 - 10.1007/s00408-017-9976-6

DO - 10.1007/s00408-017-9976-6

M3 - Article

VL - 195

SP - 217

EP - 224

JO - Lung

JF - Lung

SN - 0341-2040

IS - 2

ER -